BUP.PA - Biom'Up S.A.

Paris - Paris Delayed price. Currency in EUR
+0.06 (+0.57%)
As of 2:29PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close10.45
Bid0.00 x 0
Ask0.00 x 0
Day's range10.33 - 10.57
52-week range8.40 - 13.89
Avg. volume9,614
Market cap133.184M
PE ratio (TTM)N/A
EPS (TTM)-5.37
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.75
  • GlobeNewswire3 months ago

    Biom’up Finalizes U.S. Commercial Organization to Support U.S. Launch of HEMOBLAST™ Bellows

    SAINT-PRIEST, France, May 02, 2018 (GLOBE NEWSWIRE) -- Biom'up (BUP.PA), a specialist in surgical hemostasis, today announced it has finalized the commercial infrastructure to support the imminent launch of its lead product HEMOBLAST Bellows. The Company has recruited senior management and a large number of independent specialist sales representatives to drive the nationwide marketing and sales campaign of HEMOBLAST Bellows, which is expected to start in mid-2018. With a large team of specialists now in place, and given its clinically demonstrated high value, we are confident that HEMOBLAST Bellows will make substantial inroads and become a fixture of hemostasis in operating rooms across the USA.

  • GlobeNewswire3 months ago

    Biom’up Has Trained 200 Surgeons in its International KOL-Led Program Ahead of HEMOBLAST Bellows™ Launch

    NEW YORK and SAINT-PRIEST, France, April 24, 2018 (GLOBE NEWSWIRE) -- Biom'up (BUP.PA), a specialist in surgical hemostasis, today announced that its intensive training program to train surgeons in the use of its lead product HEMOBLAST Bellows is on track and has reached the Company’s objective of 200 trained surgeons ahead of the launch of HEMOBLAST Bellows in mid-2018. To prepare the surgical community for the imminent launch of HEMOBLAST Bellows, Biom’up ran 6 highly attended training sessions for surgeons in the U.S. and Europe, which were led by the Company’s experts in collaboration with key opinion leaders in surgical hemostasis.

  • We're sorry, but this is all we were able to find on this topic.